Zydus Lifesciences shares zoom 7% after USFDA nod for Dasatinib tabletsZydus Lifesciences share price: Zydus Lifesciences shares rose 7% following USFDA's final approval to market Dasatinib tablets across multi...
Lupin gets USFDA nod for generic cancer treatment drugLupin in partnership with Pharmascience Inc. has received approval from the US Food and Drug Administration (FDA) for Dasatinib tablets in ...
Alembic gets USFDA nod for cancer treatment drugDasatinib Tablet is indicated for the treatment of newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukaemia (CML) i...
New class of drugs may dramatically increase healthy lifespanThe researchers from The Scripps Research Institute (TSRI), Mayo Clinic and other institutions have coined the term 'senolytics' for the ne...
India, US to enhance engagement on intellectual property rights issuesBarack Obama and Narendra Modi also reaffirmed the importance of providing transparent and predictable policy environment for fostering inn...
India not to accept any probe on IPR by the US: Anand SharmaIndia reiterated that its intellectual property rights regime is fully compliant to WTO laws & the country will not take part in any unilat...
India won't participate in unilateral US probe on IPRIndia today made it clear it will not take part in any unilateral investigation by the US on its intellectual property rights (IPR).
Government cautious on cancer drug patent regimesThe commerce and industry ministry recently wrote to the health ministry, rejecting the plea that the government should issue a compulsory ...
No denial of visa to US trade commission delegation: IndiaGovernment rejected reports that it has decided not to grant visa to members of the US International Trade Commission.
India may take US to WTO if included in priority country listIndia is likely to drag the US to WTO if America includes it in the 'Priority Foreign Country' list for intellectual property rights.
US trade panel launches probe against India's trade policiesUS Federal agency USITC today started a fact finding probe into impact of Indian trade and investment policies on the American economy.
Patent office rejects BDR Pharma’s compulsory licensing applicationThe Patent Office rejected BDR’s application on the grounds that the company did not make enough efforts to obtain a voluntary licence for ...
BDR Pharmaceutical's plea for compulsory licence on cancer drug rejectedThe Indian Patent Office has rejected Mumbai-based BDR Pharmaceutical’s application for compulsory licence on cancer drug Dasatinib.
BDR seeks CL for cancer drug, offers 95% cheaper generic copyThe Mumbai-based firm has applied to the Controller of Patents, Mumbai, seeking the CL for "ease of availability" and "affordability" of th...
BDR Pharma seeks cancer drug licenceBDR Pharma has filed an application with the Mumbai Patent Office, seeking compulsory licence to market a crucial cancer drug, dasatinib
- Natco Pharma, Bristol-Myers Squibb face off in Court over sale of dasatinib clone
Hyderabad-based Natco says it has not reneged on its undertaking as its version of the drug is different and does not infringe upon the pat...
- Natco Pharma begins sales of Bristol Myers' cancer drug Dasatinib
Hyderabad-based generic drugmaker Natco Pharma has started selling copies of global pharma major Bristol Myers Squibb's cancer drug Dasatin...